{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:34Z","timestamp":1781650714252,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate whether the within-cycle sequence of neoadjuvant immunochemotherapy influences postoperative pathological response in patients with stage IIA\u2013IIIB non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively enrolled 192 patients with stage IIA\u2013IIIB NSCLC who received neoadjuvant immunochemotherapy. Patients were divided into Group A (chemotherapy on day 1 followed by immunotherapy on day 2,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009122) and Group B (immunotherapy on day 1 followed by chemotherapy on day 2,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200970). Propensity score matching (1:1, caliper\u2009=\u20090.2) created 62 matched pairs. The primary endpoint was postoperative pathological response including pathological complete response and major pathological response. Conditional logistic regression was used, and E\u2011values were calculated for sensitivity analysis. Secondary endpoints included objective response rate (ORR), safety, and perioperative outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, baseline characteristics were well balanced. The pathological response rate was higher in Group A than in Group B (50.00% vs. 30.64%; univariate OR\u2009=\u20092.33, 95%CI 1.07\u20135.09,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.033; multivariable OR\u2009=\u20094.78, 95%CI 1.24\u201318.46,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023). E\u2011value analysis suggested that the observed association may be relatively robust to unmeasured confounding (univariate E\u2009=\u20094.09, multivariable E\u2009=\u20099.03). ORR was also higher in Group A (72.58% vs. 51.65%; OR\u2009=\u20092.62, 95%CI 1.16\u20135.93,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.020). Grade\u2009\u2265\u20093 treatment\u2011related adverse events were similar between groups (35.48% vs. 29.03%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.494). Operative time was longer in Group A (180 vs. 165\u00a0min,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.037), but no differences were observed in R0 resection rate, postoperative complications, or other surgical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with stage IIA\u2013IIIB NSCLC, the within-cycle administration sequence of chemotherapy followed by immunotherapy was associated with a higher postoperative pathological response rate. This dosing sequence may have clinical optimization value, but further validation through prospective studies is still needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16028-9","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:07:38Z","timestamp":1776812858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The influence of the administration sequence of neoadjuvant immunotherapy combined with chemotherapy on the postoperative pathological response of stage IIA-IIIB non-small cell lung cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiju","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"10","key":"16028_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937\u201370. https:\/\/doi.org\/10.1002\/cac2.12359.","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"16028_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u201339. https:\/\/doi.org\/10.1038\/s41571-023-00798-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"16028_CR3","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41467-024-55068-2","volume":"16","author":"C Wang","year":"2025","unstructured":"Wang C, Li J, Chen J, Wang Z, Zhu G, Song L, et al. Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer. Nat Commun. 2025;16:1477. https:\/\/doi.org\/10.1038\/s41467-024-55068-2.","journal-title":"Nat Commun"},{"issue":"5","key":"16028_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","volume":"165","author":"R Rajaram","year":"2024","unstructured":"Rajaram R, Huang Q, Li RZ, Chandran U, Zhang Y, Amos TB, et al. Recurrence-free survival in patients with surgically resected non-small cell lung cancer: a systematic literature review and meta-analysis. Chest. 2024;165(5):1260\u201370. https:\/\/doi.org\/10.1016\/j.chest.2023.11.042.","journal-title":"Chest"},{"issue":"1","key":"16028_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/curroncol33010020","volume":"33","author":"SR Khan","year":"2025","unstructured":"Khan SR, Kotrri E, Breadner D, Kundapur V, Manna M. A Canadian perspective on perioperative systemic therapy in resectable non-small cell lung cancer. Curr Oncol. 2025;33(1):20. https:\/\/doi.org\/10.3390\/curroncol33010020.","journal-title":"Curr Oncol"},{"key":"16028_CR6","doi-asserted-by":"publisher","first-page":"104080","DOI":"10.1016\/j.critrevonc.2023.104080","volume":"190","author":"C Grant","year":"2023","unstructured":"Grant C, Hagopian G, Nagasaka M. Neoadjuvant therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2023;190:104080. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104080.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"16028_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","volume":"86","author":"JA Roth","year":"1994","unstructured":"Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86(9):673\u201380. https:\/\/doi.org\/10.1093\/jnci\/86.9.673.","journal-title":"J Natl Cancer Inst"},{"issue":"9928","key":"16028_CR8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(13)62159-5.","journal-title":"Lancet"},{"issue":"2","key":"16028_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/JTO.0000000000000062","volume":"9","author":"GK Dy","year":"2014","unstructured":"Dy GK, Bogner PN, Tan W, Demmy TL, Farooq A, Chen H, et al. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):222\u201330. https:\/\/doi.org\/10.1097\/JTO.0000000000000062.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"16028_CR10","doi-asserted-by":"publisher","first-page":"112615","DOI":"10.1016\/j.isci.2025.112615","volume":"28","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yin K, Ma R, Sun Y, Wang L, Yin D. Complex regulatory network of programmed death-ligand 1 in cancer: cancer immunomodulation from molecular mechanisms to clinical applications. iScience. 2025;28(6):112615. https:\/\/doi.org\/10.1016\/j.isci.2025.112615.","journal-title":"iScience"},{"issue":"3","key":"16028_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"issue":"21","key":"16028_CR12","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"issue":"9","key":"16028_CR13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41(9):1551\u201366. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.011.","journal-title":"Cancer Cell"},{"key":"16028_CR14","doi-asserted-by":"publisher","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 7. 2025. https:\/\/doi.org\/10.6004\/jnccn.2025.0036.","DOI":"10.6004\/jnccn.2025.0036"},{"key":"16028_CR15","volume-title":"CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer 2025","author":"Guidelines Working Committee of the Chinese Society of Clinical Oncology","year":"2025","unstructured":"Guidelines Working Committee of the Chinese Society of Clinical Oncology. CSCO guidelines for the diagnosis and treatment of non-small cell lung cancer 2025. Beijing: People\u2019s Medical Publishing House; 2025."},{"key":"16028_CR16","doi-asserted-by":"publisher","first-page":"1548665","DOI":"10.3389\/fimmu.2025.1548665","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Long J, Deng H, Chen W. Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis. Front Immunol. 2025;16:1548665. https:\/\/doi.org\/10.3389\/fimmu.2025.1548665.","journal-title":"Front Immunol"},{"issue":"3","key":"16028_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ejcts\/ezz044","volume":"56","author":"H Melek","year":"2019","unstructured":"Melek H, \u00c7etinkaya G, \u00d6zer E, Yent\u00fcrk E, Sevin\u00e7 TE, Bayram AS, et al. Pathological complete response after neoadjuvant\/induction treatment: where is its place in the lung cancer staging system? Eur J Cardiothorac Surg. 2019;56(3):604\u201311. https:\/\/doi.org\/10.1093\/ejcts\/ezz044.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"16028_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jtho.2024.10.010","volume":"20","author":"WJ Phillips","year":"2025","unstructured":"Phillips WJ, Camidge DR, Wheatley-Price P. Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy. J Thorac Oncol. 2025;20(1):30\u20133. https:\/\/doi.org\/10.1016\/j.jtho.2024.10.010.","journal-title":"J Thorac Oncol"},{"key":"16028_CR19","doi-asserted-by":"publisher","first-page":"772450","DOI":"10.3389\/fimmu.2021.772450","volume":"12","author":"W Xing","year":"2021","unstructured":"Xing W, Zhao L, Zheng Y, Liu B, Liu X, Li T, et al. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study. Front Immunol. 2021;12:772450. https:\/\/doi.org\/10.3389\/fimmu.2021.772450.","journal-title":"Front Immunol"},{"key":"16028_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jconrel.2021.12.022","volume":"341","author":"C Zhu","year":"2022","unstructured":"Zhu C, Shi Y, Li Q, Luo L, Li X, Luo Z, et al. Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect. J Control Release. 2022;341:769\u201381. https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.022.","journal-title":"J Control Release"},{"issue":"2","key":"16028_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/COC.0000000000000644","volume":"43","author":"SN Markovic","year":"2020","unstructured":"Markovic SN, Suman VJ, Javed A, Reid JM, Wall DJ, Erickson LA, et al. Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261206I. Am J Clin Oncol. 2020;43(2):115\u201321. https:\/\/doi.org\/10.1097\/COC.0000000000000644.","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"16028_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","volume":"15","author":"G Middleton","year":"2014","unstructured":"Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(14)70236-0.","journal-title":"Lancet Oncol"},{"issue":"7","key":"16028_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","volume":"19","author":"R Rami-Porta","year":"2024","unstructured":"Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(7):1007\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2024.02.011.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"16028_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"5","key":"16028_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol. 2020;15(5):709\u201340. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.005.","journal-title":"J Thorac Oncol"},{"key":"16028_CR26","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services, National Institutes of Health; 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"issue":"3","key":"16028_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar Behav Res. 2011;46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivar Behav Res"},{"issue":"1","key":"16028_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","volume":"17","author":"TL Nguyen","year":"2017","unstructured":"Nguyen TL, Collins GS, Spence J, Daur\u00e8s JP, Devereaux PJ, Landais P, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017;17(1):78. https:\/\/doi.org\/10.1186\/s12874-017-0338-0.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"16028_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/M16-2607.","journal-title":"Ann Intern Med"},{"issue":"3","key":"16028_CR30","doi-asserted-by":"publisher","first-page":"pkae021","DOI":"10.1093\/jncics\/pkae021","volume":"8","author":"NA Waser","year":"2024","unstructured":"Waser NA, Quintana M, Schweikert B, Chaft JE, Berry L, Adam A, et al. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis. JNCI Cancer Spectr. 2024;8(3):pkae021. https:\/\/doi.org\/10.1093\/jncics\/pkae021.","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"16028_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","volume":"19","author":"JB Hines","year":"2024","unstructured":"Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, et al. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable NSCLC. J Thorac Oncol. 2024;19(7):1108\u201316. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.010.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"16028_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/curroncol32070397","volume":"32","author":"TD Clementi","year":"2025","unstructured":"Clementi TD, Colonese F, Canova S, Abbate MI, Sala L, Petrella F, et al. Perioperative Chemo\/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences. Curr Oncol. 2025;32(7):397. https:\/\/doi.org\/10.3390\/curroncol32070397.","journal-title":"Curr Oncol"},{"key":"16028_CR33","doi-asserted-by":"publisher","first-page":"1572195","DOI":"10.3389\/fphar.2025.1572195","volume":"16","author":"C Li","year":"2025","unstructured":"Li C, Qi X, Yan M. Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications. Front Pharmacol. 2025;16:1572195. https:\/\/doi.org\/10.3389\/fphar.2025.1572195.","journal-title":"Front Pharmacol"},{"issue":"1","key":"16028_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54\u201361. https:\/\/doi.org\/10.1038\/nm1523.","journal-title":"Nat Med"},{"key":"16028_CR35","doi-asserted-by":"publisher","first-page":"1571212","DOI":"10.3389\/fimmu.2025.1571212","volume":"16","author":"K Fang","year":"2025","unstructured":"Fang K, Yuan S, Zhang X, Zhang J, Sun SL, Li X. Regulation of immunogenic cell death and potential applications in cancer therapy. Front Immunol. 2025;16:1571212. https:\/\/doi.org\/10.3389\/fimmu.2025.1571212.","journal-title":"Front Immunol"},{"issue":"9","key":"16028_CR36","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050\u20139. https:\/\/doi.org\/10.1038\/nm1622.","journal-title":"Nat Med"},{"issue":"5","key":"16028_CR37","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/emboj.2011.497","volume":"31","author":"AD Garg","year":"2012","unstructured":"Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31(5):1062\u201379. https:\/\/doi.org\/10.1038\/emboj.2011.497.","journal-title":"EMBO J"},{"issue":"14","key":"16028_CR38","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2217\/imt-2021-0338","volume":"14","author":"O Akdo\u011fan","year":"2022","unstructured":"Akdo\u011fan O, S\u00fctc\u00fco\u011flu O, \u00d6\u011f\u00fct B, Aky\u00fcrek N, \u00d6zdemir N, \u00d6zet A, et al. Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer. Immunotherapy. 2022;14(14):1121\u201331. https:\/\/doi.org\/10.2217\/imt-2021-0338.","journal-title":"Immunotherapy"},{"key":"16028_CR39","doi-asserted-by":"publisher","first-page":"RP99720","DOI":"10.7554\/eLife.99720","volume":"13","author":"C Liang","year":"2024","unstructured":"Liang C, Song Q, Zhou W, et al. Low-dose chemotherapy combined with delayed immunotherapy in the neoadjuvant treatment of non-small cell lung cancer and dynamic monitoring of the drug response in peripheral blood. eLife. 2024;13:RP99720. https:\/\/doi.org\/10.7554\/eLife.99720.","journal-title":"eLife"},{"issue":"1","key":"16028_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/imr.12587","volume":"280","author":"S Kumar","year":"2017","unstructured":"Kumar S, Calianese D, Birge RB. Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment. Immunol Rev. 2017;280(1):149\u201364. https:\/\/doi.org\/10.1111\/imr.12587.","journal-title":"Immunol Rev"},{"issue":"11","key":"16028_CR41","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013. https:\/\/doi.org\/10.1038\/s41419-020-03221-2.","journal-title":"Cell Death Dis"},{"issue":"9","key":"16028_CR42","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41591-024-03077-5","volume":"30","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, et al. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nat Med. 2024;30(9):2540\u20138. https:\/\/doi.org\/10.1038\/s41591-024-03077-5.","journal-title":"Nat Med"},{"issue":"8","key":"16028_CR43","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.modpat.2025.100776","volume":"38","author":"J Braden","year":"2025","unstructured":"Braden J, Potter A, Rawson RV, Adegoke NA, Lo SN, Conway JW, et al. Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort. Mod Pathol. 2025;38(8):100776. https:\/\/doi.org\/10.1016\/j.modpat.2025.100776.","journal-title":"Mod Pathol"},{"issue":"21","key":"16028_CR44","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976\u201386. https:\/\/doi.org\/10.1056\/NEJMoa1716078.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16028-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:31:09Z","timestamp":1781649069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16028-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16028"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16028-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the WMA Declaration of Helsinki and the CIOMS International Ethical Guidelines for Biomedical Research. This study was approved by the Ethics Committee of the Affiliated Hospital of North Sichuan Medical College, with the approval number being 2025ER197-1.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Due to the retrospective nature of the study, Medical Ethics Committee of the Affiliated Hospital of North Sichuan Medical College waived the need of obtaining informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"710"}}